PBYI Stock Analysis: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$7.16
-0.01 (-0.14%)
▼
5d:
-1.38%
30d:
-4.28%
90d:
+5.29%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
PBYI is down 3.8% this week, but smart money is accumulating calls. Top strike: $7.5 2026-06-18 with 717 OI. Call ratio: 88% View Scanner →
Strength: 5.6/10
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PBYI shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: PBYI shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.33
Based on -9.1% avg growth
INTRINSIC VALUE TODAY
$1.45
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $7.16, which is considered oversold relative to its 30-day fair value range of $7.18 to $7.60. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.5) compared to its historical average (11.0). At these levels, the market is pricing in 22.9% annual earnings growth.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $6.84, while resistance sits at $7.87.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $6.84, while resistance sits at $7.87.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.18 -
$7.60
Company Quality Score
55/100
(HOLD)
Options IV Signal
27th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
78.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 27th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 30.3% above Wall St target ($5.00)
- BULLISH: Expecting earnings turnaround to 22.9% growth with -2.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$7.18 -
$7.60
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.92
(12.8%)
Support & Resistance Levels
Support Level
$6.84
Resistance Level
$7.87
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.49
Wall Street Target
$5.00
(-30.3%)
Revenue Growth (YoY)
-2.6%
Earnings Growth (YoY)
-34.4%
Profit Margin
10.7%
Valuation Premium vs History
+22.9% premium
PE vs Historical
20.5 vs 11.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+22.9%
(market-implied from PE analysis)
1-Year Target
$8.81
(+23%)
2-Year Target
$10.83
(+51%)
3-Year Target
$13.31
(+86%)
3-Yr Target (if PE normalizes)
(PE: 20→11)
PE COMPRESSION
$7.15
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: -22.2%)
$5.62
(+-22%)
Base:
(SPY PE: 20.5, Growth: -22.2%)
$5.23
(-27%)
Bear:
(PE: 11.0, Growth: -22.2%)
$2.81
(-61%)
📈
Valuation based on Current Earnings
Trailing PE: 14.94 | Current EPS (TTM): $0.48
Bull Case
$5.75
(-20%)
Analyst growth -27.1%, PE expands to 16.4
Base Case
$5.23
(-27%)
Market implied -27.1%, PE stable at 14.9
Bear Case
$4.88
(-32%)
Severe decline -20.0%, PE contracts to 12.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 3:09 PM ET
Data refreshes hourly during market hours. Next update: 4:09 PM
Data refreshes hourly during market hours. Next update: 4:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan H Auerbach
SELL
18012 shares
2026-01-07
Douglas M Hunt
SELL
5014 shares
2026-01-07
Alan H Auerbach
SELL
16938 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 60 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 55 HOLD |
